Asad Haider
Showing 1–2 of 2 transcripts.
- Goldman Sachs30 min
The Healthcare Outlook: Macro Challenges and Biotech Innovations
Asad Haider, Amit Sinha, Allison Nathan
Following five years of underperformance driven by capital rotation into artificial intelligence and regulatory uncertainty regarding drug pricing, the U.S. healthcare sector is undergoing a structural correction characterized by a declining S&P 500 weighting and a shift in early-stage capital formation toward private markets. Despite these macro headwinds, specific innovation cycles in oral obesity treatments, oncology, and cardiovascular therapeutics are creating idiosyncratic opportunities, particularly within the mid-cap biotech space where investors are beginning to recognize potential for outsized returns on revenue. While large pharmaceutical firms report initial AI-driven cost savings, market participants remain cautious, awaiting tangible earnings improvements before fully re-rating assets in an environment defined by a looming patent cliff and reduced federal research funding.
- Goldman Sachs10 min
Biopharma opportunities and macro challenges: A check-up on the industry
Asad Haider, Chris Shibutani, Salveen Richter, Sylvain
Major pharmaceutical and biotech leaders converged to identify GLP-1 agonists and AI integration as primary drivers for a market revised upward to $130 billion, while strategically addressing patent cliffs through aggressive external collaborations and M&A targeting metabolic and neurology assets. Although the biotech IPO window has reopened with nine clinical-stage offerings, investor sentiment remains sensitive to interest rate trajectories and the need for immediate commercial validation of AI-driven discoveries. Consequently, industry capital allocation prioritizes balancing near-term revenue generators with long-term growth catalysts to navigate complex clinical challenges in the central nervous system and cardiovascular disease sectors.